Amgen And UCB Resubmit Biologics License Application (BLA) For Evenity (romosozumab) To The US FDA

THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news